Citation Impact
Citing Papers
Outcomes in refractory diffuse large B-cell lymphoma: results from the international SCHOLAR-1 study
2017 Standout
The 2016 revision of the World Health Organization classification of lymphoid neoplasms
2016 Standout
The Myeloma Drug Lenalidomide Promotes the Cereblon-Dependent Destruction of Ikaros Proteins
2013 StandoutScienceNobel
De novo design of immunoglobulin-like domains
2022 StandoutNobel
The PI3-Kinase Delta Inhibitor Idelalisib (GS-1101) Targets Integrin-Mediated Adhesion of Chronic Lymphocytic Leukemia (CLL) Cell to Endothelial and Marrow Stromal Cells
2013
Idelalisib—targeting PI3Kδ in patients with B-cell malignancies
2014
Discovery of GS-9973, a Selective and Orally Efficacious Inhibitor of Spleen Tyrosine Kinase
2014
A comprehensive map of molecular drug targets
2016 Standout
Toll-like Receptors and Their Crosstalk with Other Innate Receptors in Infection and Immunity
2011 Standout
CRISPR-Cas9 screens identify regulators of antibody–drug conjugate toxicity
2019 StandoutNobel
Targeting B cell receptor signalling in cancer: preclinical and clinical advances
2018
Chronic lymphocytic leukaemia is driven by antigen-independent cell-autonomous signalling
2012 Nature
Inhibition of Spleen Tyrosine Kinase Potentiates Paclitaxel-Induced Cytotoxicity in Ovarian Cancer Cells by Stabilizing Microtubules
2015
Ibrutinib-induced lymphocytosis in patients with chronic lymphocytic leukemia: correlative analyses from a phase II study
2014
The Novel Kinase Inhibitor PRT062070 (Cerdulatinib) Demonstrates Efficacy in Models of Autoimmunity and B-Cell Cancer
2014
Inflammation and tumor progression: signaling pathways and targeted intervention
2021 Standout
Apoptosis in cancer: from pathogenesis to treatment
2011 Standout
Inhibiting eukaryotic transcription. Which compound to choose? How to evaluate its activity?
2011 Standout
Treatment challenges in the management of relapsed or refractory non-Hodgkin’s lymphoma – novel and emerging therapies
2013
The JAK/STAT signaling pathway: from bench to clinic
2021 Standout
Targeting apoptosis in cancer therapy
2020 Standout
Microtubule-binding agents: a dynamic field of cancer therapeutics
2010 Standout
A metabolic labeling approach for glycoproteomic analysis reveals altered glycoprotein expression upon GALNT3 knockdown in ovarian cancer cells
2016 StandoutNobel
Oral Janus kinase/SYK inhibition (ASN002) suppresses inflammation and improves epidermal barrier markers in patients with atopic dermatitis
2019
The PI3K Pathway in Human Disease
2017 Standout
The SYK tyrosine kinase: a crucial player in diverse biological functions
2010
Single-Agent Pixantrone as a Bridge to Autologous Stem Cell Transplantation in a Patient with Refractory Diffuse Large B-Cell Lymphoma
2017 Standout
Targeting the B-cell receptor signaling pathway in B lymphoid malignancies
2014
Functional Roles of the IgM Fc Receptor in the Immune System
2019 StandoutNobel
Objective assessment of cancer genes for drug discovery
2012
Molecular pathogenesis of mantle cell lymphoma
2012
Deacetylated sialic acids modulates immune mediated cytotoxicity via the sialic acid-Siglec pathway
2021 StandoutNobel
The PI3K/mTOR inhibitor PF-04691502 induces apoptosis and inhibits microenvironmental signaling in CLL and the Eµ-TCL1 mouse model
2015
Coordinative Alignment in the Pores of MOFs for the Structural Determination of N-, S-, and P-Containing Organic Compounds Including Complex Chiral Molecules
2019 StandoutNobel
Next Generation of Fluorine-Containing Pharmaceuticals, Compounds Currently in Phase II–III Clinical Trials of Major Pharmaceutical Companies: New Structural Trends and Therapeutic Areas
2016 Standout
BCR signaling inhibitors differ in their ability to overcome Mcl-1–mediated resistance of CLL B cells to ABT-199
2016
Novel agents for the treatment of chronic lymphocytic leukemia.
2010
Relapsed/Refractory Diffuse Large B-Cell Lymphoma
2011
Diffuse large B-cell lymphoma: optimizing outcome in the context of clinical and biologic heterogeneity
2014
Heterocyclic Anticancer Compounds: Recent Advances and the Paradigm Shift towards the Use of Nanomedicine’s Tool Box
2015 Standout
Time-Resolved Luminescence Detection of Spleen Tyrosine Kinase Activity through Terbium Sensitization
2013
Superior Antitumor Activity of SAR3419 to Rituximab in Xenograft Models for Non-Hodgkin's Lymphoma
2009
Lenalidomide efficacy in activated B ‐cell‐like subtype diffuse large B ‐cell lymphoma is dependent upon IRF 4 and cereblon expression
2012
Works of Julia Schaefer-Cutillo being referenced
Novel concepts in radioimmunotherapy for non-Hodgkin's lymphoma.
2007
Inhibition of Syk with fostamatinib disodium has significant clinical activity in non-Hodgkin lymphoma and chronic lymphocytic leukemia
2009